C12orf65

Across TCGA pan-cancer cohorts, C12orf65 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C12orf65 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher C12orf65 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C12orf65 expression acts as an unfavorable survival marker.

ACC, STAD, and COAD are the cancer types where C12orf65 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	OS	Median	All	0.145	0.888	<.001	45	view →
STAD	OS	Median	All	0.001	0.667	<.001	24	view →
COAD	DFS	Median	All	0.127	0.519	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

C12orf65–ACC (OS)

Open the ACC breakdown →